Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Prelude Corporation has 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. These 5 pending office actions are distributed across 5 distinct examiners and 5 distinct art units. This distribution indicates that every active matter in the company's portfolio is being reviewed by a different individual in a unique technical group. For a practitioner, this requires a highly specialized strategy for each of the 5 pending office actions, as there is no overlap in examiners or art units.
The busiest examiner for Prelude Corporation is ILAGAN, VINCENT CAESAR, who is currently managing 1 busiest examiner pending action. With 5 distinct examiners each handling an action, the workload is perfectly spread across the portfolio. No single examiner holds more influence than another over the company's current patent prospects. Success in the Biotechnology & Pharmaceuticals area will depend on the independent outcomes of the 5 pending office actions. Practitioners must navigate the specific requirements of 5 distinct art units and the individual preferences of ILAGAN, VINCENT CAESAR and the other assigned examiners. This structure highlights the diverse technical nature of the company's biotech filings.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ILAGAN, VINCENT CAESAR | 1 | 45.0% | +73.3% |
| JONES, DAMERON LEVEST | 1 | 67.7% | +31.3% |
| TURPIN, ZACHARY MARK | 1 | 4.0% | -5.0% |
| GAO, ASHLEY HARTMAN | 1 | 56.7% | +38.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18033054 | METHODS FOR TREATING A SUBJECT WITH LOCAL INVASIVE BREAST CANCER BASED ON PDGFRB LEVELS | TURPIN, ZACHARY MARK | 134d overdue |
| 18998333 | IDENTIFICATION AND METHODS OF TREATMENT OF BREAST CANCER | ILAGAN, VINCENT CAESAR | 3d overdue |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | JONES, DAMERON LEVEST | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18998333 | IDENTIFICATION AND METHODS OF TREATMENT OF BREAST CANCER | ILAGAN, VINCENT CAESAR | 3d overdue |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | JONES, DAMERON LEVEST | — |
| 17275406 | METHOD OF SELECTION FOR TREATMENT OF SUBJECTS AT RISK OF INVASIVE BREAST CANCER | GAO, ASHLEY HARTMAN | — |
| Art Unit | Apps |
|---|---|
| 3686 | 1 |
| 1618 | 1 |
| 1682 | 1 |
| 1678 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18998333 | IDENTIFICATION AND METHODS OF TREATMENT OF BREAST CANCER | ILAGAN, VINCENT CAESAR | 3686 | §101§103 | Final Rejection | 3d overdue | Pending | Jan 24, 2025 |
| 17998334 | PD-1 AS A PREDICTIVE MARKER FOR THERAPY IN CANCER | JONES, DAMERON LEVEST | 1618 | §103§112 | Non-Final OA | — | Pending | Aug 11, 2023 |
| 18033054 | METHODS FOR TREATING A SUBJECT WITH LOCAL INVASIVE BREAST CANCER BASED ON PDGFRB LEVELS | TURPIN, ZACHARY MARK | 1682 | §102§103§112 | Final Rejection | 134d overdue | Pending | Apr 20, 2023 |
| 17275406 | METHOD OF SELECTION FOR TREATMENT OF SUBJECTS AT RISK OF INVASIVE BREAST CANCER | GAO, ASHLEY HARTMAN | 1678 | §103Other | Non-Final OA | — | Pending | Mar 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial